Preview

Ateroscleroz

Advanced search

Clinical and laboratory associations of Fas-dependant apoptosis in patients with acute and chronic coronary heart disease

Abstract

   Aim. To assess an activity of Fas-dependant apoptosis and its links with classical risk factors in patients (pts.) with acute and chronic coronary heart disease (CHD).

   Material and methods. We scrutinized 126 pts. with CHD: 84 pts. (1st group) - on 10–14th days of myocardial infarction (MI) and 42 pts. (2nd group) with stable CHD. Control group consisted of 77 volunteers without CHD and metabolic syndrome (MS). Serum levels of apoptosis activator sFasL and its inhibitor sFas were measured by ELISA. SPSS for Windows 19.0 was used.

   Results. The frequency of classical risk factors in 1st and 2nd groups did not differ significantly, both sFas (37.8 ± 24.4 vs. 22.1 ± 9.3 ng/ml, p = 0.021) and sFasL (86.2 ± 24.5 vs. 63.8±22.7 pg/ml, p < 0.001) levels being higher in 2nd group. Besides biomarkers concentrations were higher in 2nd group than in controls. In the whole cohort of CHD pts. we revealed correlations between sFas level and age (ρS = 0.330, p = 0.001), sFas and CC (ρ = – 0.591, р < 0.001) and МВ-CC (ρ = – 0.484, р < 0.001) levels. The level of sFasL correlated with HDL-С level (ρS = 0.329, p = 0.017) and was higher in arterial hypertension (79.8 ± 31.2 vs. 60.1 ± 24.1 pg/ml, p < 0.001). In the 1st group sFas/sFasL ratio was lower in pts. with full-component MS than in those with 3 components (204.7 ± 43.8 vs. 464.4 ± 196.4, p = 0.024), sFasL level being higher in DM / hyperglycemia. In the same group the number of coronary lesions appeared to be sFasL level predictor (β = 0.28, р = 0.016): F(2,65) = 496, p = 0.001. The pts. survived MI were characterized with higher sFasL level: 85.6 ± 25.4 vs. 73.3 ± 31.4 pg/ml (p = 0.001). The concentration of sFasL (ρS = – 0.362, p < 0.001) and sFas / sFasL (ρS = – 0.341, p = 0.007) correlated with post-infarction period duration.

   Conclusion. Pts. with CHD had higher sFas и sFasL levels in comparison with controls. An activity of Fas-dependant apoptosis was associated with MS, survived MI and coronary lesions confirming its role in CHD development. The levels of sFas and sFasL depended on post-infarction period duration that may be of great significance as to prevent repeated coronary events.

About the Authors

A. S. Yakovleva
Russian Ministry of Health
Russian Federation

State Budgetary Educational Institution of Higher Professional Education "Northern State Medical University"

163000

Ave. Trinity, 51

Arkhangelsk



O. A. Mirolyubova
Russian Ministry of Health
Russian Federation

State Budgetary Educational Institution of Higher Professional Education "Northern State Medical University"

163000

Ave. Trinity, 51

Arkhangelsk



References

1. Crea F., Liuzzo G. Pathogenesis of acute coronary syndromes // J. Am. Coll. Card. 2013. Vol. 61, N 1. P. 1–11.

2. Zannad F., Backer D. G., Graham I. et al. Risk stratification in cardiovascular disease primary prevention – scoring systems, novel markers, and imaging techniques // Fundam. Clin. Pharmacol. 2012. Vol. 26. P. 163–174

3. Alice P. S., Choi C. K., Choi C. K. Novel and traditional cardiovascular risk factors in adolescents // Cardiovasc. Risk Factors. 2012. P. 61–80.

4. Ogita M., Miyauchi K., Morimoto T. et al. Association between circulating matrix metalloproteinase levels and coronary plaque regression after acute coronary syndrome – Subanalysis of the JAPAN-ACS study // Atherosclerosis. 2013. Vol. 226, N 1. Р. 275–280.

5. Lutgens E., Binder C. J. Immunology of atherosclerosis // Thromb. Haemost. 2011. Vol. 106. P. 755–756.

6. Angera O., Albertsson P., Karason K. Evidence for obesity paradox in patients with acute coronary syndromes: a report from the Swedish Coronary Angiography and Angioplasty Registry // Eur. Heart J. 2013. Vol. 34. P. 345–353.

7. Васина Л. В. Клеточные и гуморальные маркеры апоптоза при остром коронарном синдроме в сочетании с гипертонической болезнью / Л. В. Васина // Артериальная гипертензия. – 2008. – Т. 14, № 4. – С. 332–335.

8. Kavathia N., Jain A., Walston J. et al. Serum markers of apoptosis decrease with age and cancer stage // Aging. 2009. Vol. 1, N 7. P. 652–663.

9. Березикова Е. Н. Влияние апоптоза на течение хронической сердечной недостаточности / Е. Н. Березикова [и др.] // Кардиология. – 2012. – № 4. – С. 55–58.

10. Blanco-Colio L. M., Martin-Ventura J. L., de Teresa E. et al. Increased soluble Fas plasma levels in subjects at high cardiovascular risk // Arteriosc. Thromb. Vasc. Biol. 2011. Vol. 27. P. 168–174.

11. Орлова О. В. Растворимые формы маркеров Fas-опосредованного апоптоза при сердечной недостаточности О. В. Орлова [и др.] // Клин. лаб. диагностика. – 2006. – № 9. – С. 38.

12. Martinet W., Kockx M. M. Apoptosis in atheroclerosis: implications for plaque destabilization // Verh. K. Acad. Geneesk. Belg. 2004. Vol. 66, N 1. P. 61–79.

13. Adamopoulos S., Parissis J. T., Georgiadis M. et al. Growth hormone administration reduces circulating proinflammatory cytokines and soluble Fas/soluble Fas ligand system in patients with chronic heart failure secondary to idiopathic dilated cardiomyopathy // J. Am. Coll. Card. 2002. Vol. 144, N 2. P. 359–364.

14. Shimizu M., Fukuo K., Nagata S. et al. Increased plasma levels of the soluble form of Fas ligand in patients with acute myocardial infarction and unstable angina pectoris // J. Am. Coll. Card. 2002. Vol. 39. P. 585–590.

15. Zhao W. S., Xu L., Wang L. F. et al. A 60-s postconditioning protocol by percutaneous coronary intervention inhibits myocardial apoptosis in patients with acute myocardial infarction // Apoptosis. 2009. Vol. 14, N 10. P. 1204–1211.

16. Deftereos S., Giannopoulos G., Kossyvakis C. et al. Effect of radiographic contrast media on markers of complement activation and apoptosis in patients with chronic coronary artery disease undergoing coronary angiography // J. Interv. Cardiol. 2009. Vol. 21, N 9. P. 473–477.

17. Boos C. J., Balakrishnan B., Blann A. D. et al. Endothelial damage/dysfunction and apoptosis in acute coronary syndromes: implications for prognosis // Thromb. Haemost. 2008. Vol. 6, N 11. P. 1841–1850.

18. Katsaros K. M., Wiesbauer F., Speidl W. S. et al. High soluble Fas and soluble Fas Ligand serum levels before stent implantation are protective against restenosis // Thromb. Haemost. 2011. Vol. 105, N 5. P. 883–891.

19. Blanco-Colio L. M., Martin-Ventura J. L., Sol J. M. et al. Decreased circulating Fas ligand in patients with familial combined hyperlipidemia or carotid atherosclerosis // J. Am. Coll. Card. 2011. Vol. 43. P. 1188–1194.

20. Kassi E., Pervanidou P., Kaltsas G. et al. Metabolic syndrome: definitions and controversies // BMC Medicine. 2011. Vol. 9. P. 48.


Review

For citations:


Yakovleva A.S., Mirolyubova O.A. Clinical and laboratory associations of Fas-dependant apoptosis in patients with acute and chronic coronary heart disease. Ateroscleroz. 2013;9(2):20-28. (In Russ.)

Views: 154


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2078-256X (Print)
ISSN 2949-3633 (Online)